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In Brief
O’Neill et al. demonstrate insulin
receptors (IRs) and IGF-1 receptors
(IGF1Rs) are required for muscle growth
but not glucose tolerance. Muscle-
specific IR/IGF1R deletion decreases
TBC1D1, thereby increasing membrane-
localized glucose transporters and
glucose uptake. However,
overexpression of a dominant-negative
IGF1R induces glucose intolerance,
indicating that protein-protein
interactions with IRs/IGF1Rs can impair
glucose homeostasis.
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Insulin and insulin-like growth factor 1 (IGF-1) arema-
jor regulators of muscle protein and glucose homeo-
stasis. To determine how these pathways interact,
we generated mice with muscle-specific knockout
of IGF-1 receptor (IGF1R) and insulin receptor (IR).
These MIGIRKO mice showed >60% decrease in
muscle mass. Despite a complete lack of insulin/
IGF-1 signaling in muscle, MIGIRKO mice displayed
normal glucose and insulin tolerance. Indeed,
MIGIRKO mice showed fasting hypoglycemia and
increased basal glucose uptake. This was secondary
to decreased TBC1D1 resulting in increased Glut4
and Glut1membrane localization. Interestingly, over-
expression of a dominant-negative IGF1R in muscle
induced glucose intolerance in MIGIRKO animals.
Thus, loss of insulin/IGF-1 signaling impairs muscle
growth, but not whole-body glucose tolerance due
to increasedmembrane localization of glucose trans-
porters. Nonetheless, presence of a dominant-nega-
tive receptor, even in the absence of functional IR/
IGF1R, induces glucose intolerance, indicating that
interactions between these receptors and other pro-
teins in muscle can impair glucose homeostasis.
INTRODUCTION
Skeletal muscle insulin resistance is a prominent feature of type 2
diabetes that precedes and predicts the development of disease
in high-risk populations (Martin et al., 1992). In humans, up to 80%
of the glucose infused during a hyperinsulinemic euglycemic
clamp is disposed into muscle. However, genetic manipulation
of insulin signaling specifically in muscle of mice has shown little
effect on whole-body glucose metabolism. For example, genetic
deletion of the insulin receptor (IR) specifically in skeletal muscle
ofmice (MIRKO) did not cause dysglycemia or diabetes, although
it did result in hypertriglyceridemiaandmildobesity (Bru¨ninget al.,
1998). On the other hand, overexpression of a kinase-deficient IR
in muscle of mice led to glucose intolerancewith increased circu-
lating insulin and triglyceride levels (Moller et al., 1996). Likewise,
mice that highly overexpress a dominant-negative, kinase-dead
insulin-like growth factor 1 (IGF-1) receptor (IGF1R) in muscle1220 Cell Reports 11, 1220–1235, May 26, 2015 ª2015 The Authors(MKR) develop severe glucose intolerance, insulin resistance,
and diabetes (Ferna´ndez et al., 2001). Further study revealed
that expression of the MKR allele impairs both insulin and IGF-1
signaling in muscle due to hybrid receptor formation, suggesting
that the normal glucose tolerance in MIRKO mice might be due
to IGF1R compensating for loss of IR signaling in muscle.
Inaddition toglucoseuptakeandmetabolism, insulin and IGF-1
signaling affect muscle growth and protein turnover (Schiaffino
andMammucari, 2011; Meek et al., 1998). Both insulin and IGF-1
have been shown to stimulate muscle protein synthesis (Fulks
et al., 1975; Rommel et al., 2001) and inhibit protein degradation
via the ubiquitin-proteasomeand autophagy-lysosomepathways
(Mammucari et al., 2007; Sandri et al., 2004). Indeed, IGF-1 treat-
ment is sufficient to cause muscle hypertrophy via Akt activation
of mTOR and inhibition of GSK3b (Rommel et al., 2001). On the
other hand, deletion of IGF1R in muscle only modestly impairs
muscle growth, suggesting alternative pathways can induce
muscle growth, possibly via IRs (Mavalli et al., 2010).
At a molecular level, insulin and IGF-1 signal through highly
homologous tyrosine kinase receptors, which are virtually ubiq-
uitously expressed in mammals. IRs and IGF1Rs specifically
bind their respective ligands at physiological concentrations.
However, at high concentrations, each ligand can bind and
initiate signaling with the opposite receptor. Both IRs and
IGF1Rs then initiate intracellular signaling via similar cascades,
beginning with tyrosine phosphorylation of insulin receptor sub-
strates (IRSs), which leads to activation of the phosphatidylinosi-
tol 3-kinase (PI3K)/Akt pathway, as well as other downstream
signals (Taniguchi et al., 2006). In addition, IR and IGF1R interact
with Src homology and collagen domain protein (Shc) to activate
mitogen-activated protein kinase pathways. Signaling via these
two pathways leads to a broad range of cellular effects on
growth, proliferation, and metabolism.
In muscle, insulin-stimulated glucose uptake has been
extensively studied. IR-mediated activation of Akt leads to phos-
phorylation of AS160 and TBC1D1 to facilitate translocation of
vesicles containing the Glut4 glucose transporter to the plasma
membrane, where they fuse, leading to increased glucose
uptake into the cell (Klip, 2009). Not surprisingly, knockout of
Glut4 in muscle of mice leads to insulin resistance and hypergly-
cemia (Zisman et al., 2000). However, basal glucose uptake, i.e.,
that which occurs in the absence of insulin, has been ascribed to
other glucose transporters, such as Glut1, which have higher
constitutive association with the sarcolemma (Scheepers et al.,
2004; Marette et al., 1992; Wang et al., 1996). Exercise is also
an important factor in glucose transport, inducing AMP-depen-
dent kinase (AMPK) activation and Glut4 vesicle translocation
via phosphorylation of AS160 and TBC1D1, which is indepen-
dent of insulin (Fujii et al., 2006; Koh et al., 2008).
To investigate to what extent insulin and/or IGF-1 signaling
pathways control glucose metabolism and protein homeostasis,
we have deleted IRs, IGF1Rs, or both in skeletal muscle using
genetic recombination. While mice with single-receptor dele-
tions show little or no change in glucose homeostasis or muscle
mass, mice with combined loss of IRs and IGF1Rs in muscle
(MIGIRKO) display dramatically decreased muscle mass and
fiber size. Nonetheless, MIGIRKO mice show normal glucose
and insulin tolerance and even have fasting hypoglycemia due
to enhanced basal glucose uptake into muscle secondary to
increased expression and translocation of glucose transporters.
Surprisingly, whenMIGIRKOmicewere crossed tomice carrying
a dominant-negative IGF1R, the resultant mice still developed
glucose intolerance and dyslipidemia. Thus, combined loss of
IRs and IGF1Rs in muscle dramatically impairs muscle growth,
but glucose tolerance is maintained by enhanced basal glucose
transport. The induction of glucose intolerance in these mice by
expression of a dominant-negative IGF1R indicates that the
dominant-negative receptor can interact with other proteins on
the cell to modify metabolic regulation.
RESULTS
Muscle-Specific Deletion of IRs and IGF1Rs Decreases
Muscle Growth and Leads to Early Demise
To generate mice with skeletal-muscle-specific deletion of IRs
and IGF1Rs, we crossedmice that express the Cre recombinase
under the control of human skeletal muscle actin promoter
(ACTA1-Cre) with mice harboring floxed IR and IGF1R alleles.
Previous attempts at deleting IRs and IGF1Rs in muscle using
Cre under the muscle creatine kinase (MCK) promoter allowed
for expression in the heart, as well as skeletal muscle, and led
to death within 21 days from cardiac failure (Laustsen et al.,
2007). Cre expression in ACTA1-Cre mice is more restricted to
skeletal muscle (Miniou et al., 1999), allowing successful gener-
ation of mice with muscle specific deletion of IRs (M-IR/),
IGF1Rs (M-IGF1R/), or both IGF1Rs and IRs (MIGIRKO) (Fig-
ure S1; Table S1). We have named mice that harbor IRlox/lox
alleles and the ACTA1-Cre transgene as M-IR/ mice in order
to distinguish them from the MIRKO mouse, which was created
using MCK-Cre (Bru¨ning et al., 1998). Genomic DNA isolated
from M-IR/ and MIGIRKO muscle (which also contains
vascular cells, fibroblasts, and satellite cells/myoblasts) showed
a 50% recombination of IRlox (Insr locus) by qRT-PCR. IGF1Rlox
(Igf1r locus) was similarly recombined by 50% in M-IGF1R/
and MIGIRKO muscle without any change in liver DNA (Figures
S1A and S1B). M-IR/ and MIGIRKO mice displayed a 90%
decrease of IR mRNA expression by qRT-PCR in muscle, while
M-IGF1R/ and MIGIRKO mice showed a 50%–60% reduction
in IGF1R mRNA (Figure S1C). These changes in IR and IGF1R
mRNA expression correlated well with decreases in protein
levels corresponding to genotype (Figure 1A).
MIGIRKO mice showed an obvious growth phenotype with
decreased body weight as early as 3 weeks of age (Figures 1BCand1C).By7 to 10weeksof age,MIGIRKOmiceexhibited severe
muscle atrophy with spinal deformities and obvious kyphosis
(Figure 1B). These mice progressed to have breathing difficulties
and died between 15 and 25 weeks of age, most likely of respira-
tory failure (Figure 1D). By contrast, M-IR/ orM-IGF1R/mice
had normal body weight and skeletal appearance and lived nor-
mally up to 52 weeks of age. By dual-energy X-ray absorptiome-
try (DEXA) scanning and assessment of tissueweight at sacrifice,
the decreased body weight inMIGIRKOmice could be attributed
almost entirely to a loss of muscle mass, with 59%–68% reduc-
tions in individual muscle weights and a 32% decreased in total
lean mass (Figures 1E–1G; Table S2). There was also a 9% loss
of lean mass and a decrease in muscle weights in M-IR/,
whereasM-IGF1R/ had normal leanmass andmuscleweights.
In addition, M-IGF1R/ and MIGIRKO mice displayed a loss of
fat mass (Figure S1D; Table S2). The cause of this loss of fat
mass is unknown, but it was not due to recombination of IRs or
IGF1Rs in fat or other tissues (Figures S1F and S1G), suggesting
some form of communication between muscle and fat that is
dependent on IGF-1 action. None of the changes in body weight
andcompositionwere attributable todwarfismoranydecrease in
linear growth as assessed by femur length (Table S2).
Histologic analysis of tibialis anterior (TA) muscle using succi-
nate dehydrogenase (SDH) staining revealed marked atrophy or
lackof hypertrophyofMIGIRKOmuscle fibers (Figure1H). The to-
tal cross sectional area of the TA was mildly reduced in M-IR/
and markedly reduced in MIGIRKOmice (Figure S2). Quantifica-
tion of fiber number normalized to the area of the TAcross section
in square millimeters revealed that the decrease in muscle size in
these two strains was due to atrophy and not a loss of muscle
fibers (Figure 1I). Lastly, while glycolytic fiber number did not
change, M-IGF1R/ and MIGIRKO mice showed increased
numbers of oxidative fibers (Figures 1J and S2C).
MIGIRKOMiceDemonstrate Normal Glucose and Insulin
Tolerance but Increased Basal Glucose Uptake in
Muscle and Fasting Hypoglycemia
Glucose levels were unchanged in randomly fed animals, but
after 16 hr of fasting, glucose levels were 35% lower in
MIGIRKO mice compared to controls (Figure 2A). This occurred
with no significant changes in either fasting or refed insulin
and triglyceride levels (Figures 2B and 2C). As expected, insu-
lin and IGF-1 signaling was abolished in skeletal muscle
from MIGIRKO animals injected with either 5 U of insulin
or 1 mg/kg IGF-1 via inferior vena cava (Figures 2D and S3A).
Insulin signaling was normal in M-IGF1R/ and blunted in
M-IR/ (Figure S3B). However, upon western blotting of mus-
cle extracts, MIGIRKO animals displayed an unexpected 3- to
10- fold increase in the protein levels of IRS-1, IRS-2, Akt1,
and Akt2. This dramatic increase was not seen at the mRNA
level, although mRNA for IRS-2 and Akt2 was increased in
MIGIRKO by 2.2- and 1.6-fold, respectively (Figure S3C). This
increase in protein levels was associated with a marked in-
crease in the amount of phosphorylated Akt in the basal state,
as well as an increase in downstream phosphorylation of
GSK3b, FoxO1, and FoxO3a (Figures 2D and S3D–S3G). We
hypothesized that other tyrosine kinases may constitutively
activate the IRS-PI3K-Akt pathway in the absence of IR andell Reports 11, 1220–1235, May 26, 2015 ª2015 The Authors 1221
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Figure 1. Deletion of IRs and IGF1Rs in Muscle Dramatically Decreases Muscle Size and Survival
(A) Western blot of insulin receptor-b (IR-b) and IGF-1 receptor-b (IGF1R-b) was measured in quadriceps from mice with muscle-specific deletion of insulin
receptor (M-IR/), IGF-1 receptor (M-IGF1R/), or both IGF-1 receptor and insulin receptor (MIGIRKO).
(B) Representative profile and hindlimb dissection of control and MIGIRKO littermate mice.
(C) Body weight was measured weekly in control and MIGIRKO mice (n = 7–16).
(D) Survival curve of MIGIRKO mice compared to control, M-IR/, and M-IGF1R/, represented as ‘‘All other genotypes’’ (n = 14–20 per group).
(E) Body weight was measured at time of sacrifice of control, M-IR/, M-IGF1R/, and MIGIRKO mice (n = 5–8 knockout mice and pooled 20 controls).
(legend continued on next page)
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IGF1R. Indeed, total EGFR levels are increased in MIGIRKO
muscle (Figure S3H).
Despite the lack of IRs and IGF1Rs in muscle, glucose toler-
ance and insulin tolerance in MIGIRKO were unchanged
compared to controls (Figures 2E and 2F). To determine the
fate of glucose in MIGIRKO animals, we performed an in vivo
glucose uptake assay under basal or insulin-stimulated condi-
tions as described in Experimental Procedures. Interestingly,
basal glucose uptake was increased in MIGIRKO muscles to
the level of insulin-stimulated control muscle, and it did not
increase further with insulin treatment (Figure 2G). In other tis-
sues, such as heart and brown adipose tissue (BAT), basal and
insulin-stimulated glucose uptake in MIGIRKO was similar to
controls, consistent with the absence of recombination of IRs
or IGFRs in these tissues (Figures S1F and S1G).
Deletion of IRs and IGF1Rs in Muscle Paradoxically
Increases Glucose Transporter Expression and
Membrane Localization
To determine the relative contributions of IR and IGF1R signaling
to insulin-stimulated glucose uptake, we measured glucose
uptake in extensor digitorum longus (EDL) and soleus muscles
in vitro. Of note, insulin signaling in these two muscle groups
was similar to quadriceps (Figure S4A). While glucose uptake
in response to insulin in EDL from M-IR/ was blunted, glucose
uptake in the soleus of M-IR/ and in EDL or soleus of
M-IGF1R/ was unchanged compared to controls (Figures 3A
and 3B). As found in vivo, in vitro basal glucose uptake was
increased in MIGIRKO muscle, and this was unresponsive to
insulin stimulation. This increase in basal glucose uptake in
MIGIRKO was associated with increased protein levels of the
glucose transporters Glut1 and Glut4 (Figures 3C and 3D). These
changes occurred with no changes in Glut1 expression at the
mRNA level and a decrease in Glut4 mRNA expression
(Figure 3E).
Since basal glucose uptake in vivo and in vitro was increased
in MIGIRKOmuscle and signaling downstream of Akt was signif-
icantly enhanced in the basal state, we hypothesized that Glut4
translocation was enhanced in fasted or unstimulated MIGIRKO
muscle. To evaluate Glut4 localization in vivo, we utilized a
method of intravital imagining of a Glut4-EGFP protein tran-
siently transfected into superficial muscle fibers of vastus latera-
lis utilizing a gene-gun approach (Lauritzen et al., 2002, 2006).
Glut4-EGFP remained in larger intracellular depots with minimal
surface localization in fibers from control mice, yet MIGIRKO
fibers displayed a diffuse pattern with dispersed GLUT4-EGFP
vesicle depots and increased surface localization (Figure 3F).
This pattern of diffuse fluorescence with increased surface local-
ization seen in MIGIRKO fibers is consistent with the pattern of(F) Representative muscle dissection from control and MIGIRKO mice.
(G) Dissected muscle weights measured from control, M-IR/, M-IGF1R/, an
(H) Representative cross section of TA muscle stained for SDH to demonstrate ox
M-IGF1R/, and MIGIRKO mice.
(I) Quantification of total number of muscle fibers normalized to cross sectional a
(J) Quantification of total oxidative and glycolytic fibers per TA section (n = 3–6 p
*p < 0.05, **p < 0.01 versus control (ANOVA). All mice were 11–15 weeks old. Qua
Gast, gastrocnemius; SDH, succinate dehydrogenase. Data are presented as m
CGlut4-EGFP seen after stimulation with insulin (Figures S4C
and S4D) or muscle contractions (Lauritzen et al., 2006, 2010).
Muscle fractionation experiments confirmed increased levels
of Glut4 and Glut1 in plasma membrane isolates from MIGIRKO
muscle compared to controls (Figure 3G). Increased Glut4 trans-
location is consistent with our observation that signaling down-
stream of Akt was increased in muscle from fasted MIGIRKO
mice (Figure 2D). MIGIRKO muscles also displayed increased
phosphorylation of AMPK in the fed state (Figure 3H), indicating
activation of this pathway. AMPK phosphorylation remained
elevated evenwhen themicewere fastedwithmodest elevations
in p-ACC, but phosphorylation of neither protein changed in
response to insulin in either control or MIGIRKO mice (Fig-
ure S4B). Despite increased basal glucose uptake and Glut4
membrane localization, lactate levels were actually decreased
in MIGIRKO muscle and glycogen content was unchanged
in M-IR/, M-IGF1R/, and MIGIRKO muscle compared to
controls (Table S3).
Deletion of IRs and IGF1Rs in Muscle Leads to
Suppression of TBC1D1, and Re-expression of TBC1D1
Leads to Re-internalization of Glut4
To gain insight into the mechanism for enhanced glucose
transporter translocation, we investigated the phosphorylation
status of AS160 and TBC1D1, both of which participate in
Glut4 translocation and glucose uptake in muscle. Consistent
with previous reports (Taylor et al., 2008), we found AS160
to be more abundant in oxidative soleus muscle and TBC1D1
more abundant in EDL, a more glycolytic muscle (Fig-
ure S4A). Phosphorylation of AS160 and TBC1D1 in response
to insulin showed no differences among control, M-IR/, and
M-IGF1R/, but basal phosphorylation of AS160 was
increased in EDL and soleus from fasted MIGIRKO mice
(Figure S4A), consistent with increased Akt phosphorylation
and activation. Interestingly, while phosphorylation of the
160-kDa band using a phospho-Akt substrate antibody (PAS
160) and AS160T642 were increased, total levels of TBC1D1
were decreased compared to controls in EDL, soleus,
and quadriceps muscle (Figures 4A and S4A). qPCR analysis
revealed a significant 20% decrease in TBC1D1 mRNA from
M-IR/ mice and a dramatic 72% decrease in MIGIRKO mus-
cle (Figure 4B). Conversely, AS160 mRNA levels were
increased 2.1- and 2.6-fold in M-IR/ and MIGIRKO muscle,
respectively.
We hypothesized that the observed decrease of total TBC1D1
levels along with increased AS160 phosphorylation in MIGIRKO
muscle contributed to the re-localization of Glut4 to the
sarcolemma. To test this hypothesis directly, we transiently
re-expressed TBC1D1 in MIGIRKO muscle (Figure S4E) andd MIGIRKO mice (n = 5–9 knockout mice and pooled 22 controls).
idative (purple) and glycolytic (gray/white) muscle fibers from control, M-IR/,
rea of TA sections in mm2 (n = 3–6 per group).
er group).
d, quadriceps; TA, tibialis anterior; EDL, extensor digitorum longus; Sol, soleus;
ean ± SEM. See also Figures S1 and S2 and Table S2.
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Figure 2. MIGIRKO Mice Display Normal Glucose Tolerance, Fasting Hypoglycemia, and Increased Basal Glucose Uptake into Muscle,
Despite Abolished Insulin Signaling in Muscle
(A) Blood glucose levels were measured in 8- to 10-week-old MIGIRKO and control mice fasted overnight or randomly fed (n = 9–10).
(B and C) Insulin (B) and triglyceride (C) levels from 8- to 10-week-old MIGIRKO and control mice fasted overnight or refed for 4 hr (n = 9–10).
(D) Insulin signaling was determined by western blot analysis in quadriceps muscle from 11- to 15-week-old MIGIRKO and control mice fasted overnight and
treated with saline or insulin intravenously.
(E and F) Intraperitoneal glucose tolerance test (GTT) (E) and insulin tolerance test (ITT) (F) were performed in 8- to 10-week-old MIGIRKO and control mice
(n = 9–10).
(G) In vivo 2-deoxyglucose uptake was performed as described in Experimental Procedures in control and MIGIRKO mice (n = 6–8 per group).
**p < 0.01 versus control (Student’s t test), #p < 0.05 versus control with same treatment, and yp < 0.05 versus basal of same genotype (ANOVA). Quad,
quadriceps; Gastroc, gastrocnemius; BAT, brown adipose tissue. Data are presented as mean ± SEM. See also Figure S3.
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Figure 3. Deletion of Muscle IRs and IGF1Rs Paradoxically Increases Glucose Transporter Expression and Membrane Localization
(A and B) Ex vivo 2-deoxyglucose uptake wasmeasured in EDL (A) and soleus (B) from 8- to 10-week-old control, M-IR/, M-IGF1R/, andMIGIRKOmice (n = 5
knockouts and 12 pooled controls).
(C and D) Glut1 (C) and Glut4 (D) total protein measured by western blot in control, M-IR/, M-IGF1R/, and MIGIRKO quadriceps (n = 4).
(E) Glut1 and Glut4 mRNA levels were measured in quadriceps from control, M-IR/, M-IGF1R/, and MIGIRKO mice by qRT-PCR (n = 5–8).
(F) Glut4-EGFP was transfected into vastus lateralis muscle and visualized 5 days later as described in Experimental Procedures. Scale bar, 10 mm (n = 2).
(G) Glut1 and Glut4 levels in plasma membrane (PM) isolates from mixed hindlimb muscle (n = 3).
(H) Phosphorylation of AMPKT172 was measured in quadriceps (n = 4).
*p<0.05, **p<0.01versuscontrol; yp<0.05versusbasal of samegenotype (ANOVA).Dataarepresentedasmean±SEM.SeealsoFigureS4andTablesS1andS3.
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Figure 4. Deletion of IRs and IGF1Rs in Muscle Leads to Suppression of TBC1D1, and Re-expression of TBC1D1 Normalizes Glut4 Locali-
zation
(A) AS160 phospho- and total protein, phospho-Akt substrate 160-kDa band (PAS 160), and TBC1D1 total protein were measured by western blot in control and
MIGIRKO quadriceps (n = 4).
(B) TBC1D1 and AS160 mRNA levels were measured in TA muscle from control, M-IR/, M-IGF1R/, and MIGIRKO mice by qRT-PCR (n = 4–8).
(C) Glut4-EGFP was transfected into vastus lateralis muscle along with empty vector (EV) or with TBC1D1, and visualized 5 days later in the fed state. Scale
bar, 10 mm.
(legend continued on next page)
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determined the localization of Glut4-EGFP using intravital
imaging of muscle fibers. Transient expression of Glut4-EGFP
with an empty vector (EV) in control muscle fibers again showed
large depots of Glut4, whereas a diffuse pattern with increased
membrane localization was seen in MIGIRKO fibers (Figure 4C).
Co-expression of TBC1D1 with Glut4-EGFP in MIGIRKO fibers
normalized the pattern of Glut4 localization back to large intra-
cellular depots. Quantification of the Glut4 depot area using
MetaMorph software was performed as described in Experi-
mental Procedures. Total area of GLUT4-EGFP vesicle depots
above 1 mm in size was lower in MIGIRKO animals compared
to controls, reflecting re-localization of the depots to t-tubules
and sarcolemma (Figures 4D and 4E). Re-expression of
TBC1D1 in MIGIRKO fibers significantly increased Glut4 depot
area compared to MIGIRKO + EV in intramyofibrillar compart-
ments (Figures 4D and 4E), where 90% of Glut4 vesicles reside
(Wang et al., 1996).
Increased Energy Expenditure in MIGIRKO Mice Is
Correlated with Increased Browning of Subcutaneous
White Fat and Increased Glucose Uptake into Fat
MIGIRKO mice display fasting hypoglycemia and increased
basal muscle glucose uptake even in the fasted state, but
glucose tolerance and insulin tolerance were normal, indicating
that whole-body metabolic adaptations are likely to occur
when insulin signaling is abolished in skeletal muscle. To better
investigate these metabolic changes, we assessed metabolic
actions of MIGIRKO mice using the Comprehensive Laboratory
Animal Monitoring System (CLAMS). This revealed that
MIGIRKO mice ate 20% less food and drank less water per
mouse than their controls, but when normalized to lean body
mass, the water intake was unchanged and the food intake
was actually increased (Figure 5A). Likewise, oxygen con-
sumption and CO2 production normalized to lean body mass
were significantly increased in MIGIRKO mice during both
day and night cycles (Figure 5B), while respiratory exchange
ratio (RER) was unchanged (Figure 5C). This occurred despite
a significant decrease in activity of the MIGIRKO mice as
measured by number of times a horizontal axis was crossed
(Figure 5D).
At sacrifice, subcutaneous white adipose tissue (sWAT) from
the inguinal region of MIGIRKO mice was noted to be more
brown in color than in normal mice, and H&E staining of
sWAT revealed large patches of adipocytes with multiloculated
lipid droplets and abundant capillaries indicating browning
of the white fat in MIGIRKO mice (Figure 5E). Consistent with
browning, mRNA expression of BAT markers such as Ucp1,
Dio2, and Elovl3 were increased by 3- to 5-fold in sWAT of
MIGIRKO mice, but not in epididymal white adipose tissue
(eWAT) (Figure 5F), basal glucose uptake was increased into
sWAT, and insulin-stimulated glucose uptake was increased
in both sWAT and eWAT (Figure 5G). Recent studies have(D and E) Quantification of average area of all Glut4 depots >1 mm from control an
with Glut4-EGFP + TBC1D1 (n = 2 control and n = 3 MIGIRKO mice per group w
*p < 0.05, **p < 0.01 versus control (ANOVA); xp < 0.05 versus MIGIRKO + EV (S
Table S1.
Cimplicated a circulating protein called irisin, which is derived
from FNDC5 and secreted from muscle, in browning of WAT
(Bostro¨m et al., 2012); however, levels of Fndc5 mRNA were
decreased in quadriceps muscle from MIGIRKO (Table S4).
FGF21 is another circulating hormone that can lead to brown-
ing of sWAT and has recently been implicated in metabolic
adaptations to autophagy inhibition in muscle (Kim et al.,
2013), as well as other stresses such as ER stress. Interest-
ingly, Fgf21 mRNA levels in quadriceps were modestly
increased, especially in the fasted state (Figure 5H), with in-
creases in mRNA levels of macrophage markers, but not ER
stress markers (Table S4). However, when we tested circulating
levels of FGF21, these were not changed in randomly fed
MIGIRKO mice (Figure 5I).
Deletion of Insulin and IGF-1 Receptors in Muscle
Does Not Predispose Mice to Diabetes, Even after
a High-Fat Diet
To determine if deletion of IRs, IGF1Rs, or both in muscle
would predispose mice to metabolic derangements or dia-
betes, all genotypes were challenged with a high-fat diet
(HFD). MIGIRKO mice were 25% smaller when dietary chal-
lenge was initiated, but mice of each genotype gained a similar
percent of weight (15%) on an HFD after 8 weeks compared to
mice on a chow diet (CD) (Figure 6A). In control mice, metabolic
derangements were present as early as 4 weeks on an HFD as
indicated by increased insulin levels and increased serum tri-
glycerides (Figure 6B). Interestingly, although serum triglycer-
ides were equally elevated in MIGIRKO mice as in controls on
an HFD, insulin levels did not increase in MIGIRKO animals
on an HFD.
Glucose tolerance tests again revealed fasting hypoglycemia
in MIGIRKO compared to controls on the same diet (Figure 6C).
However, both control and MIGIRKO mice on an HFD exhibited
impaired glucose tolerance, as measured by increased area
under the curve (AUC), with no differences between genotypes
on the same diet (Figure 6D). M-IR/ mice did show modest
impairment of glucose tolerance on CD, but similar to MIGIRKO
animals, M-IR/ and M-IGF1R/ mice became glucose intol-
erant with increased AUC on an HFD, and no differences were
observed when compared to IRlox/lox or IGF1Rlox/lox controls on
the same diet (Figures S5B and S5C). Insulin tolerance tests at
a dose of 1.0 mU/g body weight also remained similar between
control and MIGIRKO mice, regardless of diet (Figure 6E-6F).
Finally CLAMS analysis of both control and MIGIRKO animals
on an HFD revealed increases in VO2 and VCO2 compared to
CD mice, with increases in both VO2 and VCO2 in MIGIRKO
compared to controls, regardless of the diet (Figures 6G and
6H). Both control and MIGIRKO mice showed the expected
suppression of RER on an HFD indicating increased fat utiliza-
tion, with no differences between genotypes on the same diet
(Figure 6I).d MIGIRKO mice transfected with Glut4-EGFP + EV and MIGIRKO transfected
ith three to seven fibers each).
tudent’s t test). Data are presented as mean ± SEM. See also Figure S4 and
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Figure 5. Increased Energy Expenditure in MIGIRKO Mice Is Associated with Browning of Subcutaneous Fat
(A) Daily food and water intake were measured in control and MIGIRKO animals and normalized per mouse or per milligram of lean body weight (LBW) (n = 9–10).
(B) Oxygen consumption (VO2) and carbon dioxide production (VCO2) per kg of LBW were measured using CLAMS metabolic cages (n = 9–10).
(C) Respiratory exchange ratio (RER) was measured in control and MIGIRKO mice (n = 9–10).
(D) Activity was measured as the number of times an animal crossed a horizontal laser (n = 9–10).
(E) H&E staining was performed on inguinal subcutaneous white adipose tissue (sWAT) from control and MIGIRGO animals.
(F) Markers of brown adipose tissue (BAT) were measured by qRT-PCR in sWAT and epididymal WAT (eWAT); (n = 6).
(G) In vivo 2-deoxyglucose uptake under basal or insulin-stimulated conditions was measured in sWAT and eWAT from control and MIGIRKO mice (n = 6–8).
(legend continued on next page)
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Overexpression of a Dominant-Negative IGF1R in
Muscle of MIGIRKO Mice Leads to Metabolic
Derangements, Despite the Absence of IRs and IGF1Rs
Previous studies have shown that mice overexpressing a domi-
nant-negative, kinase-inactive IGF1R in muscle (MKR) develop
overt diabetes, presumably through inhibition of endogenous
IR and IGF1R function (Ferna´ndez et al., 2001). To further explore
this hypothesis, we expressed the mutant IGF1R in MIGIRKO
muscle by crossing MKR and MIGIRKO mice (MKR-MIGIRKO).
As has been previously reported (Ferna´ndez et al., 2002), we
observed that MKR mice have reduced body weight compared
to controls (Figure 7A). Unlike MKR mice on an FVB background
(Ferna´ndez et al., 2001), MKR mice on this mixed genetic back-
ground exhibited no differences in glucose levels upon fasting or
refeeding (Figures 7B and 7C); however, they did develop signif-
icant glucose intolerance when compared to controls (Figures
7D and 7E). Expression of the MKR allele in MKR-MIGIRKO
mice did not further reduce the body weight of MIGIRKO mice
(Figure 7A), nor did it affect the development of mild hypoglyce-
mia upon fasting when compared to control and MKRmice (Fig-
ure 7B). However, upon refeeding for only 4 hr, MKR-MIGIRKO
mice displayed an exaggerated rebound in glucose levels.
Interestingly, expression of the dominant-negative IGF1R in
MKR-MIGIRKO mice also resulted in development of glucose
intolerance in MIGIRKO mice, similar to that observed when
the MKR transgene was expressed in control mice (Figures 7D
and 7E). The impaired glucose tolerance in MKR and MKR-
MIGIRKO mice was associated with elevated circulating triglyc-
erides, similar to that observed in HFD-fed animals (Figure S6A),
but with no significant change in insulin levels (Figure S6B).
Surprisingly, MKR-MIGIRKO show decreased Glut1 levels
compared to MIGIRKO (Figure 7C), but the total level was similar
to that observed in MKR. By contrast, MKR-MIGIRKO muscle
shows markedly increased levels of Glut4 protein compared to
control andMKRmice, which were similar to what was observed
in MIGIRKO muscle.
We determined in vivo glucose uptake during an intravenous
glucose tolerance test (IV GTT) to seewhich tissuesmay account
for the changes in glucose tolerance in MKR-MIGIRKO mice.
Glucose values during the IV GTT again demonstrated mild but
significant glucose intolerance in MKR compared to controls
and glucose intolerance in MKR-MIGIRKO compared to
MIGIRKOs (Figure S6C). Glucose uptake into quadriceps and
gastrocnemius muscle during IV GTT was unchanged in MKR
mice compared to controls (Figure 7F). MIGIRKO and MKR-
MIGIRKO mice showed increased glucose uptake in skeletal
muscle compared to control mice with no changes between
MIGIRKO and MKR-MIGIRKO muscle. Interestingly, glucose
uptake into heart was significantly decreased in MKR and
MKR-MIGIRKO mice compared to controls (Figure 7F), whereas
no change was observed in other insulin-sensitive tissues (Fig-
ure S6D). As previously observed for other genes on the MCK(H) Fgf21 mRNA levels from quadriceps of MIGIRKO and control mice either ran
(I) Serum FGF21 levels in randomly fed control and MIGIRKO mice (n = 5).
*p < 0.05, **p < 0.01 versus control (Student’s t test); #p < 0.05 versus control with
presented as mean ± SEM. See also Table S1 and S4.
Cpromoter (Bru¨ning et al., 1998), expression of the MKR allele
was very high in both skeletal muscle and heart as shown by
IGF1R western blot analysis (Figure 7G). Total levels of Akt iso-
forms, as well as phosphorylation of Akt, in MKR-MIGIRKO
skeletal muscle were the same as MIGIRKO, but these levels
were elevated compared to that observed in control and MKR
skeletal muscle and did not respond to insulin or IGF-1 treatment
(Figures 7G and S7). However, insulin signaling in heart as
measured by phosphorylation of Akt, GSK3b, and FoxO isoforms
was unchanged (Figure 7G), indicating that changes in Akt
signaling in MKR and MKR-MIGIRKO hearts are unlikely to
account for the impaired glucose uptake when compared to
controls.
DISCUSSION
Skeletal muscle insulin resistance is an important component in
the pathogenesis of type 2 diabetes and metabolic syndrome,
and it may occur years prior to onset of disease (Martin et al.,
1992). However, while deletion of IRs in skeletal muscle of
MIRKO mice causes some features of the metabolic syndrome,
it alone does not cause diabetes or hyperglycemia (Bru¨ning
et al., 1998). Two potential explanations for this discrepancy
are the possibility that there is residual insulin signaling in muscle
via the IGF1R or that exercise-induced glucose uptake compen-
sates for this insulin resistance and maintains glucose uptake.
Consistent with the first hypothesis, Ferna´ndez et al. (Ferna´ndez
et al., 2001) have reported that MKR mice, which overexpress a
dominant-negative form of the human IGF1R in muscle, develop
diabetes at a young age, suggesting that this receptor can
hybridize with IRs and IGF1Rs to block insulin and IGF-1
signaling and induce hyperglycemia.
To test the first hypothesis directly, in the present study, we
specifically deleted IRs and IGF1Rs in muscle to create the
MIGIRKO mouse. Indeed, we find that IRs and IGF1Rs compen-
sate for each other to maintain muscle growth, such that when
both are deleted, the mice display no insulin or IGF-1 signaling
in skeletal muscle and have a marked decrease in muscle
mass and fiber size. Despite this, these mice display normal
whole-body glucose tolerance, indicating that, in mice, neither
of these receptors alone or in combination is required in muscle
to maintain normal glucose tolerance. Furthermore, loss of IRs
and IGF1Rs in muscle does not lead to diabetes, even when
themice are challengedwith an HFD. That is not to say that these
MIGIRKO mice do not display perturbations in muscle glucose
metabolism. To the contrary, MIGIRKOmice show fasting hypo-
glycemia, which is mediated by increased glucose transporter
protein levels and translocation leading to increased basal
glucose uptake in muscle. Furthermore, energy expenditure
was increased and associated with increased glucose up-
take in BAT, WAT, and increased markers of browning of
sWAT, possibly contributing to the normal glucose tolerance indomly fed or fasted for 16 hr were measured by qRT-PCR ( n = 4 per group).
same treatment, yp < 0.05 versus basal of same genotype (ANOVA). Data are
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Figure 6. MIGIRKO Mice Are Not Predisposed to Diabetes, Even after High-Fat Diet Feeding
(A) Body weights of control and MIGIRKO mice were measured weekly while on a chow diet (CD) or high-fat diet (HFD) beginning at 6 weeks of age (n = 4–8).
(B) Serum insulin levels from randomly fed mice and triglycerides from overnight fasted control and MIGIRKO mice on a CD or HFD for 4 weeks (n = 4–8).
(C and D) Intraperitoneal glucose tolerance test (GTT) (C) was performed and area under the curve (AUC) (D) was calculated for MIGIRKO and control mice on a
CD or HFD for 9 weeks (n = 3–9).
(E and F) Intraperitoneal insulin tolerance test (ITT) (E) was performed and area above the curve (AAC) (F) was calculated for mice on a CD or HFD for 8 weeks
(n = 3–9).
(G–I) VO2 (G), VCO2 (H), and RER (I) were measured in animals on a CD or HFD during both light and dark cycles using CLAMS metabolic cages (n = 3–9).
*p < 0.05 versus control with same diet, yp < 0.05 versus CD of same genotype (Student’s t test). Data are presented as mean ± SEM. See also Figure S5.MIGIRKO mice. Surprisingly, despite the lack of effect of IR/
IGF1R knockout in muscle on whole-body glucose tolerance,
expression of the dominant-negative IGF1R in muscle does
lead to glucose intolerance and some of the metabolic derange-1230 Cell Reports 11, 1220–1235, May 26, 2015 ª2015 The Authorsments associated with metabolic syndrome. Thus, insulin
signaling via the IGF1R in muscle is not a compensatory mech-
anism by which glucose tolerance is maintained when the IR is
deleted in muscle.
Mechanistically, this study defines a critical role for IRs/
IGF1Rs in muscle to suppress basal glucose transport, espe-
cially in the fasted state (low insulin). Normally, muscle utilizes
glucose for energy production primarily in the fed state and tran-
sitions to fatty acids as a primary fuel source upon fasting. Upon
refeeding, the muscle rapidly switches back to glucose
utilization in a paradigm termed metabolic flexibility (Storlien
et al., 2004). One component of muscle metabolic flexibility is
the activation of glucose transport by insulin, which occurs via
enhanced Glut4 translocation. Somewhat unexpectedly, we
find that the total absence of IR and IGF1R signaling leads to a
paradoxical increase in Glut1 and Glut4 proteins and increased
localization of these to the plasma membrane, even in the fasted
state. Thus, the MIGIRKOmouse develops mild fasting hypogly-
cemia, rather than hyperglycemia.
Several mechanisms contribute to the increased basal
glucose uptake in muscle following loss of IRs and IGF1Rs. First,
deletion of IRs/IGF1Rs in muscle leads to decreased levels of
TBC1D1. TBC1D1 is a Rab-GAP protein expressed primarily
in glycolytic muscle and is homologous to the Rab-GAP AS160
(also known as TBC1D4) (Taylor et al., 2008). Both AS160 and
TBC1D1 are inhibited by Akt- or AMPK-mediated phosphoryla-
tion to promote GLUT4 translocation to the plasma membrane
(Taylor et al., 2008). We observe that re-expression of TBC1D1
in MIGIRKO muscle in vivo is able to reverse the abnormal
Glut4 localization. These data are further supported by in vitro
studies, which show that silencing of TBC1D1 in L6 myotubes
or adipocytes results in increased basal Glut4 and Glut1 translo-
cation, respectively (Zhou et al., 2008; Ishikura and Klip, 2008).
Interestingly, germline deletion of TBC1D1 results in decreased
glucose uptake in muscle, which was consistently associated
with decreased Glut4 levels (Dokas et al., 2013; Szekeres
et al., 2012). In MIGIRKO mice, we find decreased levels of
TBC1D1 protein but increased levels of Glut1 and Glut4, which
are related to decreased protein turnover, as mRNA levels
were unchanged or decreased. In addition, Akt and AMPK are
chronically activated in MIGIRKO muscle, which was unex-
pected and may relate to energy stress, changes in protein turn-
over, or unmasking of a feedback loop. While little is known
about the control of TBC1D1 expression, our data indicate that
IR/IGF1R signaling plays an important role in the regulation of
TBC1D1 and AS160 levels in muscle.
It has been known for some time that IGF-1 treatment can
induce muscle hypertrophy via the Akt-mTOR pathways, yet
previous studies have indicated that deletion of IGF1Rs alone
in muscle only modestly changes myocyte size and morphology
(Schiaffino and Mammucari, 2011; Mavalli et al., 2010). The
present study indicates that signaling via either IRs or IGF1Rs
is sufficient to maintain muscle mass. This indicates that phys-
iologic levels of insulin or IGF-1 ligand are sufficient to promote
proteins synthesis and suppress protein degradation as long as
either the IR or the IGF1R are present. Recent work has identi-
fied FoxO transcription factors, which are known targets for IR/
IGF1R signaling, as critical mediators of muscle protein degra-
dation and atrophy (Mammucari et al., 2007; Sandri et al.,
2004).
The browning of the sWAT in MIGIRKO mice also contributes
to the metabolic phenotype. Previous reports confirm thatCchanges in the autophagy pathway in muscle can lead to in-
creases energy expenditure via FGF21 induced browning of
WAT (Kim et al., 2013). Although circulating FGF21 levels were
not increased, local FGF21 production by the muscle remains
a possible mechanism for the browning of sWAT observed in
these mice. These mice were raised at room temperature
(25C), which is not thermo-neutral, and the reduced body size
may contribute to increased need for thermogenic capacity.
Our work also identifies a distinction between lack of IR/IGF1R
signaling and insulin resistance in which the receptors are
present but activation by ligand is decreased. Thus, while com-
bined deletion of muscle IRs and IGF1Rs does not alter glucose
or insulin tolerance in mice, expression of a dominant-negative
IGF1R in skeletal muscle (and heart) in both control and
MIGIRKO mice can produce mild glucose intolerance and lipid
abnormalities. This is similar to previous observations demon-
strating that MKR mice develop diabetes associated with dysli-
pidemia, hepatic steatosis, and insulin resistance (Kim et al.,
2003; Vaitheesvaran et al., 2010), but in our study, this occurs
even in mice lacking normal insulin and IGF1Rs in muscle.
We speculate that at least two possibilities contribute to this
phenomenon. First, the dominant-negative IGF1R may bind to
a receptor other than IR/IGF1R, such as Met (Fafalios et al.,
2011), or to one or more downstream signaling proteins, such
as IRS-1 and Shc, to transmit a signal to the myocyte that
actively perturbs lipid homeostasis and interrupts tissue cross-
talk, whereas deletion of the receptors does not transmit such
a signal. Second, cardiac insulin/IGF-1 resistance, when com-
bined with skeletal muscle resistance, may contribute to more
glucose intolerance and lipid abnormalities than seen with skel-
etal muscle insulin resistance alone.
Our lab has previously shown that deletion of IRs/IGF1Rs in
preadipocytes protects them from apoptosis and reintroduction
of a non-functional IR transmitted a signal that conferred sus-
ceptibility to apoptosis (Boucher et al., 2010). This suggests
that the unoccupied insulin and IGF1Rs can generate a signal
that is different from that normally mediated by the occupied
receptor. The current study likewise indicates that deletion of
IRs or IGF1Rs is fundamentally different from loss of insulin or
IGF-1 signaling in which the receptors are present but the ligand
or ligands are missing. Further work will be needed to fully char-
acterize the nature of the signals coming from unoccupied insulin
and IGF1Rs and the specific IR/IGF1R receptor-protein interac-
tions that contribute to metabolic disease.
In summary, our study demonstrates that IR or IGF1R signaling
is critical for normal muscle growth but that deletion of both re-
ceptors in muscle does not lead to impaired glucose tolerance
due to underlying feedback loops, which maintain a high level
of glucose uptake, even in the fasted/unstimulated state. In addi-
tion, deletion of IRs and IGF1Rs inmuscle is unable to induce dia-
betesorworsenmetabolic parameters inmicechallengedwith an
HFD.On theother hand, lossof IRs and IGF1Rs inmuscle leads to
increased basal glucose uptake due to increases in levels of
Glut1 and Glut4 transporters, chronic activation of Akt and
AMPK signaling, and a loss of TBC1D1 expression. Finally, we
find that the presence of a non-functional IGF1R in muscle of an-
imals lacking IRs and IGF1Rs can induce glucose intolerance and
metabolic derangements, indicating a novel mechanism ofell Reports 11, 1220–1235, May 26, 2015 ª2015 The Authors 1231
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Figure 7. Overexpression of a Dominant-Negative, Kinase-Inactive IGF1R in Muscle of MIGIRKO Mice Induces Glucose Intolerance and
Impaired Glucose Uptake in Heart
(A) Body weight was measured in 8- to 10-week-old control mice, mice with overexpression of a kinase inactive IGF1R in muscle (MKR), MIGIRKO mice, and
MKR-MIGIRKO mice (n = 3–7).
(B) Blood glucose was measured in 8- to 10-week-old control, MKR, MIGIRKO, and MKR-MIGIRKO mice after an overnight fast and after 4 hr of refeeding
(n = 3–7).
(C) Glut1 and Glut4 were measured in quadriceps (n = 8–10).
(D and E) Intraperitoneal glucose tolerance test (GTT) (D) was performed and area under the curve (AUC) (E) was calculated for 7- to 15-week-old mice (n = 4–7).
(legend continued on next page)
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altered signaling by this receptor mutant. These data add a new
layer of understanding, such that the metabolic changes that
occur in insulin-resistant statesmay be a consequence of signals
transmitted from a poorly functional IR or IGF1R in muscle.
Further investigation of the protein interactions of IRs and IGF1Rs
in the insulin-resistant statewill potentially providenew targets for
the treatment of type 2 diabetes and its complications.
EXPERIMENTAL PROCEDURES
Animal Care and Use
Animal studies were performed according to protocols approved by the Insti-
tutional Animal Care and Use Committee (IACUC). Male mice were used for all
studies other than MKR-MIGIRKO studies, which used both males and fe-
males. Muscle IR knockout (M-IR/), muscle IGF1R knockout (M-IGF1R/),
and combined muscle IR/IGF1R knockout (MIGIRKO) mice were each gener-
ated by crossing mice carrying the Cre recombinase driven by a skeletal
muscle actin promoter, ACTA1-Cre (Jackson Laboratory, stock number
006149), with mice carrying both floxed insulin and IGF1R receptor alleles
(Boucher et al., 2012), i.e., IRlox/loxIGF1Rlox/lox, then maintained as separate
colonies. Since no differences were observed among the IRlox/lox, IGF1Rlox/lox,
IRlox/+IGF1Rlox/lox, and IRlox/loxIGF1Rlox/lox mice, the results on controls were
pooled. MKR transgenic mice, which have themurine MCK promoter directing
expression of the human IGF1R gene containing the K1003R mutation, were
purchased from Jackson Laboratory (stock number 016618) and have been
previously described (Ferna´ndez et al., 2001). See the Supplemental Experi-
mental Procedures for more information.
In Vivo Glucose Uptake
Glucose uptake into tissue was measured by intravenous injection with either
saline or 1 mU/g insulin in combination with 0.33 mCi [14C]2-deoxyglucose/g
administered via the retro-orbital sinus. After 45 min, [14C] levels in blood
and tissue were determined. For full details, see the Supplemental Experi-
mental Procedures.
Ex Vivo Muscle Glucose Uptake
Glucose uptake was measured in EDL and soleus strips as previously
described (Hayashi et al., 1998). Briefly, mice were fasted starting at 22:00
and muscle harvested the next day between 10:00 and 13:00. EDL and
isolated soleus strips were incubated with resting tension in the basal state
or stimulated with 5 mU/ml of insulin for 40 min with the addition of [3H]-2-de-
oxyglucose for the last 10 min.
Plasmid Transfection and Intravital Microscopy
The construction of GLUT4-EGFP (Lauritzen et al., 2002, 2008) and TBC1D1
(An et al., 2010) have been described previously. Mice were transfected using
the Helios gene gun system (Bio-Rad) as previously described (Lauritzen
et al., 2002; Lauritzen, 2010; Lauritzen and Schertzer, 2010). Briefly, mice
were anaesthetized with 90 mg/kg pentobarbital; the skin was opened to
expose the vastus lateralis to the bombardment of DNA/gold particles using
the gene gun. Five days after transfection, vastus lateralis in random-fed mice
were imaged. Quantification of Glut4-EGFP vesicular depots above 1 mm in
size and measurement of average GLUT4-EGFP area were generated using
MetaMorph software. See the Supplemental Experimental Procedures for
more information.
Physiological and Analytical Measurements
CLAMS (Columbus Instruments) and DEXA measurements were performed
at the Joslin Diabetes Research Center (DRC) core. Glucose tolerance tests(F) In vivo 2-deoxyglucose uptake was performed during an IV GTT in control,
(G) Western blots for IGF1R expression and insulin signaling were performed on
after insulin injection via IVC.
*p < 0.05, **p < 0.01 versus control (ANOVA), #p < 0.05 versus MIGIRKO (Stude
Cand insulin tolerance tests were performed as previously described (Bru¨ning
et al., 1998). Insulin levels were measured using a mouse insulin ELISA kit
(Crystal Chem), triglycerides were measured using a triglyceride assay kit
(Abnova), and FGF21 serum levels were measured with a mouse/rat ELISA
kit (R&D Systems, catalog number MF2100). In vivo insulin and IGF-1
signaling was performed in anesthetized, overnight-fasted mice by injecting
either 5 U of regular insulin or 1 mg/kg of human IGF-1 (Sigma-Aldrich) via
inferior vena cava (IVC). Then, 10–15 min later, tissues were harvested and
snap frozen in liquid nitrogen. Lactate levels were measured in gastrocne-
mius at the Mayo Clinic Metabolomics Resource Core using time-of-flight
mass spectrometry.
Statistical Analyses
All data are presented as mean ± SEM. Student’s t test was performed for
comparison of two groups, and ANOVA was performed for comparison of
three or more groups to determine significance.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.04.037.
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